Supported by Luitpold Pharmaceuticals, Inc., Shirley, NY.
Evaluation of Polysulfated Glycosaminoglycan for the Treatment of Hip Dysplasia in Dogs
Article first published online: 28 JUN 2008
Volume 23, Issue 3, pages 177–178, May 1994
How to Cite
HAAN, J. J. D., GORING, R. L. and BEALE, B. S. (1994), Evaluation of Polysulfated Glycosaminoglycan for the Treatment of Hip Dysplasia in Dogs. Veterinary Surgery, 23: 177–178. doi: 10.1111/j.1532-950X.1994.tb00468.x
Presented at the 20th Annual Veterinary Orthopedic Society Conference, Lake Louise, Canada, February 27-March 6, 1993.
- Issue published online: 28 JUN 2008
- Article first published online: 28 JUN 2008
- Cited By
A double-blinded, controlled clinical study was performed to compare the response of adult dogs affected with hip dysplasia to a placebo and three different dosages of polysulfated glycosaminoglycan (PSGAG): 2.2 mg/kg, 4.4 mg/kg, and 8.8 mg/kg. Dogs were randomly assigned to treatment groups. The drug was administered intramuscularly every 3 to 5 days for a total of eight injections. Response to treatment was analyzed based on changes in lameness, range of motion (ROM), and pain on manipulation of the hip joints. Evaluation for adverse reactions included complete blood cell (CBC) count, blood urea nitrogen (BUN), creatinine, and physical examination. Data were collected on a total of 111 dogs. Eighty-four met all criteria for inclusion in the study. Dogs that were given 4.4 mg/kg of PSGAG showed the greatest improvement in orthopedic scores, whereas dogs in the placebo group showed the smallest improvement; however, the differences in clinical improvement between the four treatment groups were not statistically significant. No local or systemic adverse reactions related to the drug were observed.